1990 Mary-Claire King of the University of California at Berkeley discovers the location of BRCAI gene.
1994 The complete sequence of BRCAI gene is identified, including specific mutations related to hereditary breast and ovarian cancer, by a collaborative effort led by Mark Skolnick at the University of Utah Medical Center.
1994 Myriad Genetics--a company founded by University of Utah scientists--files for patent on BRCA1.
1995 The location of the BRCA2 gene is discovered in a collaborative effort led by a team from Institute of Cancer Research, UK.
1995 The most common BRCAI mutation is traced back to families of Ashkenazi Jewish descent Subsequently, additional two mutations--one in BRCA0 and one in BRCA2--are traced to Ashkenazi Jews.
1996 The complete sequence of the BRCA2 gene is identified by Myriad Genetics, and the role of the BRCA2 gene is identified in male breast cancer. Myriad Genetics files BRCA2 patent.
1996 BRACAnalysis[R], the first commercial test for BRCAI and BRCA2 mutations, becomes commercially available from Myriad Genetics.
1997 The U.S. Patent Office issues a patent for BRCAI to Myriad Genetics.
1997 The BRCA2 mutation is linked to prostate cancer.
1998 The U.S. Patent Office issues BRCA2 patent to Myriad Genetics.
1998 Study shows that reoccurrence of breast cancer in patients with BRCA1 in the opposite breast was four to five times as frequent compared to breast cancer survivors lacking the BRCA1 mutation.
1999 Researchers demonstrate that surgical removal...